These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4382 related articles for article (PubMed ID: 29492876)

  • 41. Antibiotic and Modulation of Microbiota: A New Paradigm?
    Rizzatti G; Ianiro G; Gasbarrini A
    J Clin Gastroenterol; 2018; 52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017():S74-S77. PubMed ID: 29912755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets.
    Tie Y; Huang Y; Chen R; Li L; Chen M; Zhang S
    Gut Microbes; 2023 Dec; 15(2):2265028. PubMed ID: 37822139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The emerging role of the gut microbiota and its application in inflammatory bowel disease.
    Wang X; Peng J; Cai P; Xia Y; Yi C; Shang A; Akanyibah FA; Mao F
    Biomed Pharmacother; 2024 Oct; 179():117302. PubMed ID: 39163678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease.
    Wasilewski A; Zielińska M; Storr M; Fichna J
    Inflamm Bowel Dis; 2015 Jul; 21(7):1674-82. PubMed ID: 25822014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biotherapy Using Probiotics as Therapeutic Agents to Restore the Gut Microbiota to Relieve Gastrointestinal Tract Inflammation, IBD, IBS and Prevent Induction of Cancer.
    Dahiya D; Nigam PS
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed.
    Larussa T; Abenavoli L; Fabiano G; Mancuso MA; Polimeni N; Dumitrascu DL; Luzza F
    Minerva Gastroenterol (Torino); 2021 Dec; 67(4):357-368. PubMed ID: 35040302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IBD and the gut microbiota--from bench to personalized medicine.
    Bellaguarda E; Chang EB
    Curr Gastroenterol Rep; 2015 Apr; 17(4):15. PubMed ID: 25762474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gut dysbacteriosis and intestinal disease: mechanism and treatment.
    Meng X; Zhang G; Cao H; Yu D; Fang X; de Vos WM; Wu H
    J Appl Microbiol; 2020 Oct; 129(4):787-805. PubMed ID: 32277534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.
    Takahashi K; Morita N; Tamano R; Gao P; Iida N; Andoh A; Imaeda H; Kurokawa K; Tsuboi M; Hayakawa Y; Fujishiro M; Shinkura R
    J Gastroenterol; 2024 Sep; 59(9):812-824. PubMed ID: 38874761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.
    Yadav A; Yadav R; Sharma V; Dutta U
    Indian J Gastroenterol; 2024 Feb; 43(1):112-128. PubMed ID: 38409485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The gut microbiota, a new cardiovascular risk factor?].
    Chong-Nguyen C; Duboc H; Sokol H
    Presse Med; 2017; 46(7-8 Pt 1):708-713. PubMed ID: 28756077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Gut microbiota and chronic inflammatory bowel disease].
    Konturek PC
    MMW Fortschr Med; 2022 Jul; 164(Suppl 7):12-15. PubMed ID: 35831743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut microbiome a promising target for management of respiratory diseases.
    Trivedi R; Barve K
    Biochem J; 2020 Jul; 477(14):2679-2696. PubMed ID: 32726437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Probiotics and antibiotics in IBD.
    Sokol H
    Dig Dis; 2014; 32 Suppl 1():10-7. PubMed ID: 25531348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases.
    Sundin J; Öhman L; Simrén M
    Psychosom Med; 2017 Oct; 79(8):857-867. PubMed ID: 28422780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Probiotics, prebiotics and amelioration of diseases.
    Tsai YL; Lin TL; Chang CJ; Wu TR; Lai WF; Lu CC; Lai HC
    J Biomed Sci; 2019 Jan; 26(1):3. PubMed ID: 30609922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation.
    Amoroso C; Perillo F; Strati F; Fantini MC; Caprioli F; Facciotti F
    Cells; 2020 May; 9(5):. PubMed ID: 32429359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 220.